Toxoplasma gondii infection among chronic hepatitis C patients: a case-control study
Hala A El-Nahas1, Nora L El-Tantawy1, Raghda E Farag1
1Faculty of Medicine, Mansoura University, Egypt.
Insights
Chronic hepatitis C (HCV) patients show high rates of Toxoplasma gondii (T. gondii) infection, particularly IgG antibodies. This opportunistic infection warrants consideration in HCV patient management and follow-up.
Area of Science:
- Medical Microbiology
- Hepatology
- Infectious Diseases
Background:
- Chronic hepatitis C virus (HCV) infection is a significant global health concern.
- HCV patients may be susceptible to opportunistic infections due to altered immune status.
- Toxoplasma gondii (T. gondii) is an opportunistic parasite with potential implications in immunocompromised individuals.
Purpose of the Study:
- To investigate the prevalence of anti-Toxoplasma gondii (T. gondii) IgG and IgM antibodies in Egyptian patients with chronic HCV.
- To assess the association between T. gondii infection and the stage of liver disease (cirrhosis) in HCV patients.
- To explore correlations between T. gondii seropositivity and HCV viral load.
Main Methods:
- Serum samples were collected from 120 chronic HCV patients (early and late-stage) and 40 healthy controls.
- Enzyme-linked immunosorbent assay (ELISA) was used to detect anti-T. gondii IgG and IgM antibodies.
- Real-time RT-polymerase chain reaction (RT-PCR) quantified hepatitis C virus (HCV) RNA levels.
Main Results:
- High seropositivity rates for anti-T. gondii IgG were observed in chronic HCV patients (92.6% in late-stage, 76.9% in early-stage) compared to controls (15%).
- Anti-T. gondii IgM antibodies showed no significant difference in prevalence across patient groups and controls.
- A significant correlation was found between high IgG levels and higher HCV viral loads (P=0.026).
Conclusions:
- Chronic HCV patients exhibit a high prevalence of Toxoplasma gondii IgG antibodies, suggesting increased susceptibility.
- Opportunistic T. gondii infection poses a potential risk to chronic HCV patients, especially those with advanced liver disease.
- Toxoplasmosis screening and management should be considered in the comprehensive care of chronic HCV patients.
Objective:
To determine the detection rate of anti-Toxoplasma gondii (T. gondii) IgG and IgM in chronic HCV patients attending the Department of Tropical Medicine Mansoura University hospital in Egypt.
Methods:
This study included 120 adult chronic HCV patients, 81 decompensate cirrhosis (late-stage) and 39 chronic HCV non cirrhotic patients (early-stage) and 40 healthy blood donors as controls. Serum samples were examined for anti-Toxoplasma IgM and anti-Toxoplasma IgG antibodies by ELISA. Real-time RT-polymerase chain reaction assay was done for quantitation of hepatitis C virus.
Results:
Anti-T. gondii IgG antibodies were detected in 75 (92.6%) of 81 late-stage cirrhotic patients, 30 (76.9%) of the 39 chronic HCV non cirrhotic patients (early-stage) and in 6 (15%) of 40 controls with statistically significant difference (P<0.001). Anti-T. gondii IgM antibodies were found in 11 (13.6%) in late stage patients, 5 (12.8%) in early stage and in 3 (7.5%) of controls with no statistical significant difference (P=0.610). There was no correlation between stage of fibrosis and IgM or IgG antibodies positivity in our studied groups (P=0.526). High IgG levels significantly correlated with high viral load (P=0.026).
Conclusions:
Our findings suggest that the serious opportunistic T. gondii infection represent a potential significant risk for chronic HCV patients. So, toxoplasmosis should be considered in their investigations and follow-up.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Hepatic Encephalopathy
Chronic Pancreatitis II: Pathophysiology


